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Summary
Background Evidence for a beneﬁ t of interventions to help women who screen positive for intimate partner violence 
(IPV) in health-care settings is limited. We assessed whether brief counselling from family doctors trained to respond 
to women identiﬁ ed through IPV screening would increase women’s quality of life, safety planning and behaviour, 
and mental health.
Methods In this cluster randomised controlled trial, we enrolled family doctors from clinics in Victoria, Australia, and 
their female patients (aged 16–50 years) who screened positive for fear of a partner in past 12 months in a health and 
lifestyle survey. The study intervention consisted of the following: training of doctors, notiﬁ cation to doctors of women 
screening positive for fear of a partner, and invitation to women for one-to-six sessions of counselling for relationship 
and emotional issues. We used a computer-generated randomisation sequence to allocate doctors to control (standard 
care) or intervention, stratiﬁ ed by location of each doctor’s practice (urban vs rural), with random permuted block sizes 
of two and four within each stratum. Data were collected by postal survey at baseline and at 6 months and 12 months 
post-invitation (2008–11). Researchers were masked to treatment allocation, but women and doctors enrolled into the 
trial were not. Primary outcomes were quality of life (WHO Quality of Life-BREF), safety planning and behaviour, 
mental health (SF-12) at 12 months. Secondary outcomes included depression and anxiety (Hospital Anxiety and 
Depression Scale; cut-oﬀ  ≥8); women’s report of an inquiry from their doctor about the safety of them and their 
children; and comfort to discuss fear with their doctor (ﬁ ve-point Likert scale). Analyses were by intention to treat, 
accounting for missing data, and estimates reported were adjusted for doctor location and outcome scores at baseline. 
This trial is registered with the Australian New Zealand Clinical Trial Registry, number ACTRN12608000032358.
Findings We randomly allocated 52 doctors (and 272 women who were eligible for inclusion and returned their 
baseline survey) to either intervention (25 doctors, 137 women) or control (27 doctors, 135 women). 96 (70%) of 
137 women in the intervention group (seeing 23 doctors) and 100 (74%) of 135 women in the control group (seeing 
26 doctors) completed 12 month follow-up. We detected no diﬀ erence in quality of life, safety planning and behaviour, 
or mental health SF-12 at 12 months. For secondary outcomes, we detected no between-group diﬀ erence in anxiety at 
12 months or comfort to discuss fear at 6 months, but depressiveness caseness at 12 months was improved in the 
intervention group compared with the control group (odds ratio 0·3, 0·1–0·7; p=0·005), as was doctor enquiry at 
6 months about women’s safety (5·1, 1·9–14·0; p=0·002) and children’s safety (5·5, 1·6–19·0; p=0·008). We recorded 
no adverse events.
Interpretation Our ﬁ ndings can inform further research on brief counselling for women disclosing intimate partner 
violence in primary care settings, but do not lend support to the use of postal screening in the identiﬁ cation of those 
patients. However, we suggest that family doctors should be trained to ask about the safety of women and children, 
and to provide supportive counselling for women experiencing abuse, because our ﬁ ndings suggest that, although we 
detected no improvement in quality of life, counselling can reduce depressive symptoms.
Funding Australian National Health and Medical Research Council. 
Introduction
WHO endorses primary care as a setting for early inter-
vention in intimate partner violence (IPV), which is a 
major public health issue.1 Family doctors are often the 
ﬁ rst professional group that women speak with about such 
problems,2 but restricted evidence exists to guide doctors’ 
responses to women who screen positive for IPV.2,3 Despite 
policy recommendations for health-care screening,4 evi-
dence suggests that such screening without oﬀ ering 
structured intervention to those iden tiﬁ ed has little eﬀ ect.2,5 
A systematic review3 identiﬁ ed ﬁ ve trials in which an 
intervention was oﬀ ered after screening in health-care 
settings. The one primary care screening trial included in 
this review showed no eﬀ ect of a nurse-led management 
protocol compared with the use of a wallet-sized referral 
card on reducing IPV.6 Thus, evidence informing response 
in primary care is based on very few trials, with little focus 
on clinically important outcomes for women.2,3
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In this trial, we addressed this evidence gap by assessing 
the eﬀ ect of a brief counselling intervention oﬀ ered by 
family doctors to women identiﬁ ed through IPV screening 
in Australia. Counselling interventions should not be 
expected to decrease violence in women’s lives in the short-
term,7 which suggests that measuring abuse as a primary 
outcome in trials or referral to IPV-related services might 
be problematic. We hypothesised that the intervention will 
increase women’s perceived support and comfort to 
discuss abuse and thus lead to positive changes in women’s 
self-eﬃ  cacy and to improvements in women’s safety 
planning and behaviours, mental health, and quality of 
life. In this Article, we report the main ﬁ ndings of this trial 
at 6-months and 12-months follow-up.
Methods
Study design and participants
Our protocol is described elsewhere.8 Brieﬂ y, we did a 
cluster ran domised controlled trial enrolling family 
doctors and their female patients who screened positive 
for IPV; the trial conforms to the CONSORT guidelines.9 
Doctors were recruited between Jan 31, 2008, and Jan 18, 
2010; doctors and their female patients were randomised 
between Sept 22, 2008, and June 18, 2010. 6 month data 
collection occurred from Aug 26, 2009, to June 24, 2011, 
and 12 month data collection from March 18, 2010, to 
Nov 24, 2011. Family doctors were the unit of random-
isation, to minimise con tamination that could otherwise 
occur if trained doctors were seeing both intervention 
and control patients. Outcomes were measured at the 
individual level; those considered to be clinically 
meaningful and selected as our primary measures were 
quality of life, safety planning and behaviour, and 
mental health.2,10
We sent doctors (one per practice) from urban (710 
[71%] of 1004 doctors) and rural (294 [29%] of 1004 doctors) 
Victoria, as listed by the Australian Medical Publishing 
Company, written invitation to participate in the trial. 
Doctors were eligible for inclusion if they worked three or 
more sessions per week, used electronic records, and if 
70% or more of their patients spoke English. For every 
doctor recruited, women (aged 16–50 years) who had 
visited the doctor in past 12 months were mailed a brief 
survey from the practice (done by researchers).8 The 
survey assessed the frequency of eight health and life style 
issues, including how often in the past 12 months they 
were afraid of their partner or ex-partner (ﬁ ve-point Likert 
scale: “none of the time”, “a little”, “some”, “most”, “all of 
the time”).11 This item has been shown to have good 
sensitivity and speciﬁ city for the identiﬁ cation of women 
who have experienced physical, emotional, or sexual 
abuse.12 We did not send a health and lifestyle survey to 
women for whom we had no address or if their doctor 
anticipated diﬃ  culties in responding because of cognitive 
impairment or poor English-language skills. Women who 
screened positive for fear of their partner and provided 
contact details were eligible for the trial and were invited 
to participate by telephone by re searchers. Further 
exclusions were undertaken at this point: if patients had 
misinterpreted the fear item, had experienced fear but 
not in the past 12 months, had insuﬃ  cient English-
language skills, or were no longer seeing the trial doctor 
(ﬁ gure). Eligible women who agreed to participate were 
mailed an information leaﬂ et, resources card, and 
baseline survey to a nominated safe address. We excluded 
otherwise eligible doctors if no women were enrolled 
from the practice. We randomly allocated doctors (and 
their patients) once all baseline data were collected.
The study intervention13 consisted of the following: 
training of doctors, notiﬁ cation to doctors of women 
screening positive for fear of a partner, and invitation to 
women for brief counselling for relationship and 
emotional issues (appendix). The counselling inter vention 
was based on the Psychosocial Readiness Model,14 which 
acknowledges that abused women might not be ready or 
able to take advantage of referrals oﬀ ered by providers.15 
There is an opportunity for health prac titioners to facilitate 
a woman’s shift towards changing her IPV situation.16 
When designing the intervention, we consulted the 
following sources: systematic reviews of health-care-based 
interventions,2 meta-analysis of qualitative studies,17 and 
international IPV primary care guidelines.18
Doctors in the intervention group received the Healthy 
Relationships Training programme, designed to train 
them to respond to women and deliver a brief counselling 
intervention (appendix). Training consisted of a 6-h 
distance learning package and two 1-h interactive practice 
visits delivered by an academic clinician using simulated 
patient role plays.13 Training emphasised the importance 
of  patient-centred care and promoted active listening, 
motivational interviewing, and problem-solving tech-
niques for validating women’s experiences and feelings, 
assessing readiness for change, and supporting deci-
sions.13 Women attending the practices of doctors in the 
intervention group who were fearful of a partner were 
sent a letter from the doctor to invite them to attend 
between one and six counselling sessions (depending on 
women’s needs) over a 6 month period at no cost to the 
patient. Doctors in both groups (intervention and control) 
received a basic IPV education pack and Continuing 
Professional Development points. All women received a 
list of resources (with the surveys) and women in the 
control group received usual care if they presented to 
their doctor with concerns during the trial period.
Data were collected via postal survey 6 months and 
12 months after sending the initial counselling invi-
tation. Primary outcome measures were: WHO Quality 
of Life-BREF (four dimensions);19 mental health score 
SF-12;20 patients’ response to whether or not they had 
ever made a safety plan (appendix); and responses to a 
Safety-Promoting Behaviour Checklist.21 Secondary 
outcomes included depression and anxiety (Hospital 
Anxiety and Depression Scale; cut-oﬀ  ≥8);22 women’s 
report of an inquiry from their doctor about the safety of 
For the protocol see www.
biomedcentral.com/1471-
2458/10/2
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Figure: Trial proﬁ le
ITT=intention to treat. 
*Primary analysis imputed 
missing cases. †Analysis 
includes women who returned 
surveys only.
20 100 women (attending 55 doctors) sent health and lifestyle survey 
 14 137 did not return survey
 221 surveys returned undelivered
 5742 women returned survey and were assessed for trial eligibility
52 doctors (272 women) randomised
731 women (attending 55 doctors) screened positive (fearful of partner) 
477 women (attending 53 doctors) provided contact information
5011 women excluded (negative screen) 
25 doctors (137 women) allocated to intervention (mean cluster size 
 5·5; range 1–16) 
27 doctors (135 women) allocated to control (mean cluster 
 size 5; range 1–14)
254 women excluded (no contact information)
 2 doctors excluded (no eligible patients identiﬁed)
386 women (attending 52 doctors) eligible for trial entry
 91 women excluded (ineligible)
 1 doctor excluded (no eligible patients identiﬁed)
114 women excluded:
 39 refused
 19 could not be contacted
 1 missed screening cutoﬀ date
 55 did not return baseline survey
 2 doctors excluded (patients did not respond)
43 women excluded
 2 lost to follow-up 
 14 withdrewc 
 27 did not return 6 month survey 
 2 doctors excluded (patients did not respond)
36 women excluded:
 2 lost to follow-up 
 5 withdrew 
 29 did not return 6 month survey
137 women in primary ITT analysis at 6 months*
 23 doctors (94 women) in complete case analysis 
  (mean size 4·1; range 1–13)†
135 women in primary ITT analysis at 6 months* 
 25 doctors (99 women) in complete case analysis 
  (mean size 4·0; range 1–10)†  
 2 doctors excluded (patients did not respond)
25 women excluded
 3 withdrew 
 22 did not return 12 month survey 
 1 doctor excluded (patients did not respond)
28 women excluded
 2 withdrew 
 26 did not return 12 month survey
137 women in primary ITT analysis at 12 months* 
 23 doctors (96 women) in complete case analysis
  (mean size 4·2; range 1–14)†
135 women in primary ITT analysis at 12 months*
 26 doctors (100 women) in complete case analysis
   (mean size 3·8; range 1–10)†  
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them and their children; and comfort to discuss fear 
with their doctor (ﬁ ve-point Likert scale). We have not 
yet analysed the open-ended questions (at 6 months and 
12 months) about readiness for change. Other variables 
included IPV (Composite Abuse Scale; cut-oﬀ  ≥7),12 
harm (items from Consequences of Screening Tool),23 a 
harm or beneﬁ t visual analogue scale (VAS), perceived 
doctor support VAS, and health and community service 
use (appendix).
Ethics approval was granted by The University of 
Melbourne’s Human Research Ethics Committee. Safety 
of women was a foremost concern (appendix): women 
were contacted at times nominated by them, using safe 
addresses and phone numbers to minimise the likelihood 
of their partners becoming aware of the intervention. All 
women received resource cards, and a distress protocol 
was followed for women and researchers. The data 
monitoring committee monitored the trial’s integrity and 
assessed women’s wellbeing through annual meetings in 
which they reviewed outcome and harm data.
Randomisation and masking
A statistician who was otherwise not involved in the 
study follow-up generated a random allocation sequence 
in Stata,24 stratiﬁ ed by location of each doctor’s practice 
(urban vs rural), with random permuted block sizes of 
two and four within each stratum (appendix). Doctors 
were assigned unique identiﬁ er codes so that the 
statistician was masked to group allocation. The 
statistician randomly allocated doctors to a study group, 
with the trial coordinator (LOD) notifying doctors to their 
allocation. The allocation sequence was fully protected 
until doctors and women had consented, provided 
baseline data, and enrolled. Because of the nature of the 
intervention, neither doctors nor patients could be 
masked to intervention, but study investigators and 
researchers following-up patients and entering and 
analysing data were masked to allocation.
Statistical analysis
Our calculated sample size was 136 women from 
34 practices (four women per practitioner; appendix). 
This calculation was based on a two-sample t test, 
allowing for a design eﬀ ect of 1·08 due to clustering 
(intra-cluster correlation of 0·02) and variable cluster 
size. We increased the number of doctors to 40 
(160 women) to allow for loss of clusters. As estimated 
in the protocol,8 this was suﬃ  cient for at least 80% 
power (α 5%, two-sided test), to detect clinically 
important diﬀ erences on the primary outcomes. We 
hypothesised a diﬀ erence between the two arms at 
12 months of 0·5 SDs on the WHO Quality of Life-
BREF (SD=20), mental health SF-12 (SD=11) and safety 
behaviours (SD=2·5), and a 30% diﬀ erence in 
proportion with safety plans (40% vs 10%). We used 
descriptive statistics to summarise doctors’ and 
women’s characteristics and outcomes at baseline, 
6 months, and 12 months by study group. We report 
intracluster cor relations for key baseline variables 
estimated by one-way analysis of variance. Doctors were 
the main sampling unit, and doctors and women were 
analysed in the groups to which they were originally 
assigned. All continuous outcomes followed a broadly 
normal distribution, except for the number of safety 
behaviours (0–15; appendix) which had a strong right-
skewed distribution, and were therefore dichotomised 
Intervention Comparison Total Australian 
average 
Family doctors
Number 25 27 52 25 707
Urban* 18 (72%) 19 (70%) 37 (71%) 89%
Women 14 (56%) 18 (67%) 32 (62%) 39%
Age in years 49·3 (8·4) 46·9 (7·7) 48·1 (8·1) 49·3
Works in group practice 23 (92%) 27 (100%) 50 (96%) 88% 
Hours per week in clinical practice 36·6 (11·6) 30·0 (12·1) 33·6 (12·1) 38·3 
Graduated in Australia 19 (83%) 18 (78%) 37 (80%) 74%
GPAQ communication score† 81·4 (19·3) 81·7 (19·0) 81·6 (19·1) 84·0‡
Time in years since graduation 24·6 (8·6) 22·3 (8·3) 23·5 (8·4) ··
Years as a family doctor 18·4 (8·5) 16·8 (7·3) 17·6 (7·9) ··
Mental health skills training
Level 1 (2 h) 7 (28%) 6 (22%) 13 (25%) ··
Level 2 (≥6 h) 5 (20%) 4 (15%) 9 (17%) ··
Total training about intimate partner violence§
0–2 h 12 (48%) 12 (44%) 24 (46%) ··
3–5 h 8 (32%) 6 (22%) 14 (27%) ··
6–10 h 2 (8%) 5 (19%) 7 (14%) ··
Women§
Number 137 135 272 ··
Mean age in years 37·9 (8·8) 39·1 (7·3) 38·5 (8·1) ··
Marital status
Married 33 (25%) 50 (37%) 83 (31%) ··
Separated or divorced 51 (38%) 48 (36%) 99 (37%) ··
Never married 50 (37%) 36 (27%) 86 (31%) ··
Lives with a partner 66 (48%) 78 (58%) 144 (53%) ··
Children (younger than 18 years) at home 73 (53%) 86 (64%) 159 (59%) ··
Year 12 schooling not completed 51 (38%) 63 (47%) 114 (42%) ··
Unemployed 32 (27%) 41 (33%) 73 (30%) ··
Pension as main income source 29 (22%) 32 (25%) 61 (23%) ··
English not ﬁ rst language 8 (6%) 7 (5%) 15 (6%) ··
Fearful most or all the time 21 (15%) 17 (13%) 38 (14%) ··
Positive for abuse on CAS (total score ≥7) 101 (75%) 93 (71%) 194 (73%) ··
Severe combined abuse on CAS 42 (31%) 46 (35%) 88 (33%) ··
Physical and emotional abuse¶ on CAS 40 (30%) 30 (23%) 70 (26%) ··
Emotional abuse¶ only on CAS 37 (27%) 34 (26%) 71 (27%) ··
Physical abuse only on CAS 2 (2%) 3 (2%) 5 (2%) ··
Data are n, n (%), or mean (SD). Data for Australian averages are mean or percent. CAS=Composite Abuse Scale. 
GPAQ=General Practice Assessment Questionnaire. *Rural, Remote, and Metropolitan Areas classiﬁ cation 1–2. 
†As rated by trial participants before randomisation—scores are expressed as a percentage of the maximum possible 
score (100) for communication, with higher scores indicating greater satisfaction. ‡Data from reference 33. 
§Denominators vary due to missing data. ¶Emotional abuse, harassment, or both.
Table 1: Baseline characteristics of family doctors and women
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(0–5 and 6–15). For continuous outcomes, we used a 
linear mixed eﬀ ects model in which study group was 
ﬁ tted as a ﬁ xed eﬀ ect, and data for doctors and women 
were treated as random eﬀ ects to account for the 
correlation of responses of women attending the same 
practice and correlation of repeated outcome measures 
(at 6 months and 12 months) for women, respectively. 
We used marginal logistic regression with generalised 
esti mating equations with information sandwich esti-
mates of SEs, adjusting for correlated responses at the 
doctor-level for binary outcomes. Multivariable regres-
sion analysis adjusted for stratiﬁ cation (urban vs rural) 
and the baseline outcome.25 We used multiple impu-
tation to account for missing data (appendix). We did 
analyses of complete cases and multiply imputed data 
in Stata (version 12).24 Analyses reported were pre-
speciﬁ ed,8 apart from the multiple imputation.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Study group Unadjusted Adjusted† Adjusted† with missing 
imputation
Intervention Comparison Estimated 
eﬀ ect size‡ 
(95% CI)
p value Estimated 
eﬀ ect size‡ 
(95% CI)
p value Estimated eﬀ ect 
size‡ (95% CI)
p value
N Mean (SD) 
or n (%)
N Mean (SD) 
or n (%)
WHO Quality of Life-BREF
Physical
Baseline 136 59·5 (20·7) 135 58·3 (17·5)
6 months 94 64·2 (22·4) 99 60·2 (18·0) 5·1 (–0·5 to 10·7) 0·08 5·2 (1·3 to 9·0) 0·008 4·9 (1·1 to 8·6) 0·01
12 months 96 63·5 (22·2) 100 62·2 (18·8) 1·9 (–3·6 to 7·5) 0·50 2·1 (–1·7 to 5·9) 0·28 2·7 (–1·4 to 6·8) 0·20
Psychological
Baseline 136 50·0 (18·4) 135 48·4 (18·1)
6 months 94 54·3 (19·9) 99 52·1 (17·6) 3·2 (–2·0 to 8·3) 0·23 2·4 (–1·1 to 6·0) 0·18 2·5 (–1·2 to 6·2) 0·19
12 months 96 55·4 (20·4) 100 53·0 (17·3) 2·2 (–2·9 to 7·4) 0·39 2·2 (–1·3 to 5·7) 0·23 2·3 (–1·5 to 6·1) 0·23
Social
Baseline 137 47·7 (23·5) 135 47·0 (24·6)
6 months 94 54·5 (24·9) 99 50·2 (23·4) 4·6 (–2·0 to 11·3) 0·17 4·6 (–1·1 to 10·3) 0·12 4·8 (–1·0 to 10·7) 0·11
12 months 96 54·9 (23·9) 100 52·4 (23·8) 2·0 (–4·6 to 8·6) 0·56 2·2 (–3·5 to 7·8) 0·46 2·1 (–4·3 to 8·5) 0·52
Environmental
Baseline 136 59·4 (15·4) 135 58·0 (15·8)
6 months 94 62·5 (16·4) 99 61·9 (16·0) 0·3 (–4·9 to 5·4) 0·93 1·2 (–2·8 to 5·1) 0·57 1·0 (–2·6 to 4·7) 0·57
12 months 96 64·1 (17·0) 100 63·5 (15·5) 0·5 (–4·7 to 5·7) 0·85 1·9 (–2·0 to 5·8) 0·35 1·9 (–1·7 to 5·5) 0·29
SF-12
Mental Health Status
Baseline 130 36·6 (11·9) 129 35·9 (11·9)
6 months 93 38·6 (12·1) 92 37·4 (11·6) 1·3 (–2·2 to 4·7) 0·46 0·9 (–2·3 to 4·1) 0·60 0·8 (–2·3 to 3·9) 0·61
12 months 94 41·0 (13·0) 94 38·4 (12·2) 2·6 (–0·9 to 6·0) 0·15 2·3 (–0·8 to 5·5) 0·15 2·4 (–1·0 to 5·7) 0·17
Other
More than ﬁ ve safety behaviours§
Baseline 136 31 (23%) 131 38 (29%)
6 months 92 6 (7%) 97 10 (10%) 0·6 (0·2 to 1·8) 0·37 0·8 (0·3 to 2·3) 0·63 0·9 (0·3 to 3·0) 0·89
12 months 95 45 (47%) 96 50 (52%) 0·8 (0·5 to 1·5) 0·52 0·8 (0·5 to 1·5) 0·49 1·0 (0·5 to 2·1) 0·92
Ever had a safety plan
Baseline 137 34 (25%) 133 32 (24%)
6 months 93 34 (37%) 98 31 (32%) 1·2 (0·7 to 2·2) 0·57 1·1 (0·6 to 2·2) 0·71 1·0 (0·4 to 2·5) 0·91
12 months 95 43 (45%) 97 27 (28%) 2·0 (1·1 to 3·5) 0·03 2·4 (1·2 to 4·9) 0·01 1·7 (0·8 to 4·0) 0·20
Some denominators vary because of missing data. Estimated intra-cluster correlation for all the baseline outcomes were truncated to zero. *Primary outcomes were 
measured at 12 months. †Adjusted for outcome measures at baseline and practice location. ‡Mean diﬀ erence for WHO quality of life-Bref and SF-12 and odds ratios for other. 
§Proportion of women who reported implementing more than ﬁ ve safety behaviours in the past 6 months, on the Safety Promoting Behaviour Checklist. 
Table 2: Primary outcomes*
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Results
We randomly allocated 52 doctors (and 272 women) to 
either intervention or control (ﬁ gure).26 Compared with the 
average for Australian family doctors,27,28 doctors in this 
trial were more likely to be women and from rural practices 
(table 1).26,29 Baseline characteristics of doctors and women 
were much the same between the intervention and control 
groups (table 1), as were the response rates to the 6-month 
and 12-month follow-up surveys (ﬁ gure). Scores for both 
primary and secondary outcomes were also much the 
same between women in the two groups (tables 1 and 2). 
Baseline characteristics of women retained and those lost 
to follow-up at 12 months were similar between study 
groups (appendix). Of the 137 women invited for coun-
selling, 67 women (49%) attended 160 appointments 
(median of one visit, range one to six). 29 women (21%) 
had not attended an appointment at 6 months despite 
three reminder calls. 41 women refused to attend—nine of 
these women felt they did not need counselling, nine were 
busy or not interested, eight had moved locality, seven had 
counselling elsewhere, ﬁ ve were dissatisﬁ ed with their 
study doctor, and three were unprepared to discuss the 
reasons for their refusal.
We detected no between-group diﬀ erence in quality of 
life, safety plans or behaviours, or mental health SF-12 at 
12 months (table 2). Most estimated intervention eﬀ ects 
for the complete case and multiple imputation analyses 
were much the same, except for ever having a safety plan, 
suggesting that multiple imputation corrects for an 
upward bias in the odds ratio estimated using complete 
cases only. In terms of the secondary outcomes (table 3), 
fewer women in the intervention arm had depressive 
symptoms at 12 months; more women reported an 
inquiry from their doctor about safety of women and 
safety of children at 6 months. We recorded no between-
group diﬀ erence in anxiety symptoms or comfort to 
discuss fear of partner with the doctor (table 3).
The number of women who had a Composite Abuse 
Scale of 7 or more decreased in both groups from baseline 
(101 [75%] of 135 women in the intervention group and 
93 [71%] of 132 women in the control group) to month 12 
(44 [47%] of 93 women in the intervention group and 
40 [42%] of 96 women in the control group). Table 4 shows 
the assessment of harms and beneﬁ ts related to women’s 
participation in the trial. Most women agreed that they 
were glad they participated, and for half of them the 
quality of their life was somewhat better or better. Several 
women described negative and positive partner behav-
iours when their partner became aware they were in the 
trial, but we detected no between-group diﬀ erence. More 
Study group Unadjusted Adjusted† Adjusted† with missing 
imputation
Intervention Comparison ICC Odds ratio 
(95% CI)
p value Odds ratio 
(95% CI)
p value Odds ratio 
(95% CI)
p value
n n (%)* n n (%)*
HADS depression score ≥8‡ 0§
Baseline 136 62 (46%) 134 69 (52%)
6 months 94 34 (36%) 98 45 (46%) 0·6 (0·3–1·1) 0·09 0·6 (0·3–1·1) 0·08 0·4 (0·1–1·0) 0·05
12 months 96 39 (41%) 99 57 (58%) 0·5 (0·3–0·9) 0·01 0·4 (0·2–0·8) 0·006 0·3 (0·1–0·7) 0·005
HADS anxiety score ≥8‡ 0·014 
Baseline 136 98 (72%) 134 94 (70%)
6 months 94 61 (65%) 98 68 (69%) 0·7 (0·4–1·3) 0·29 0·6 (0·3–1·2) 0·14 0·5 (0·2–1·3) 0·14
12 months 96 61 (64%) 99 66 (67%) 0·9 (0·5–1·6) 0·67 0·8 (0·4–1·6) 0·55 0·4 (0·2–1·2) 0·11
Enquiry from doctor about woman’s safety¶ 0·02
Baseline 136 17 (13%) 133 19 (14%)
6 months 93 30 (32%) 96 12 (13%) 3·3 (1·5–6·9) 0·002 3·5 (1·7–7·5) 0·001 5·1 (1·9–14·0) 0·002
12 months 94 19 (20%) 99 11 (11%) 2·1 (0·9–4·7) 0·09 2·1 (0·9–4·7) 0·08 2·7 (0·9–7·5) 0·07
Enquiry from doctor about child’s safety|| 0·05
Baseline 73 6 (8%) 84 15 (18%)
6 months 43 16 (37%) 61 11 (18%) 2·8 (1·1–6·9) 0·03 6·0 (1·7–20·5) 0·005 5·5 (1·6–19·0) 0·008
12 months 51 11 (22%) 69 6 (9%) 2·2 (0·8–6·2) 0·14 3·8 (1·1–13·3) 0·04 4·4 (1·0–20·7) 0·06
Comfort to discuss fear** 0·03
Baseline 136 82 (60%) 133 85 (64%)
12 months 96 60 (63%) 98 65 (66%) 0·8 (0·4–1·6) 0·59 0·9 (0·5–1·8) 0·79 0·9 (0·5–1·7) 0·75
HADS=hospital anxiety and depression scale. ICC=intra-cluster correlation for baseline outcome. *Some denominators vary because of missing data. †Adjusted for outcome measures at baseline and practice 
location. ‡HADS score ≥8—outcome timepoint was 12 months. §ICC was truncated at zero. ¶As reported by woman (denominator includes all women who returned the survey, even if they had not visited the 
trial doctor in the past 6 months; outcome timepoint was 6 months). ||As reported by woman (denominator includes women with children younger than 18 years, who returned the survey, even if they had not 
visited the trial doctor in the past 6 months (outcome timepoint was 6 months). **Measured only at baseline and 12 months. 
Table 3: Secondary outcomes
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detailed analysis of the speciﬁ c eﬀ ect of surveys (appen-
dix), shows that even at baseline 40% of women felt the 
survey had “made them more open to dealing with 
possible relationship problems” in both groups. Further-
more, 4586 (80%) of 5742 women who returned the 
screening survey and 229 (84%) of 272 women enrolled 
into the trial stated that it was acceptable or very acceptable 
to be asked about fear of their partner in a survey. We 
detected no between-group diﬀ erence in terms of 
the harm-beneﬁ t VAS (intervention mean score=79·5 
[SD 17·4]; comparison mean 74·6 [19·2]; adjusted 
diﬀ erence 5·0 (85% CI –0·2 to 10·2), p=0·06). Perceived 
support from doctors at 6 months was higher in the 
intervention group than it was in the control group 
(intervention mean VAS 50·3 [SD 38·5]; comparison 
mean 35·4 [34·9]; adjusted diﬀ erence 16·0 (3·4 to 28·7), 
p=0·01). We detected no diﬀ erence in the proportion of 
women using the trial doctor or other counselling or IPV 
services between groups (appendix).
Discussion
In our trial, brief counselling from family doctors trained 
to respond to women identiﬁ ed through IPV screening 
did not improve women’s quality of life, safety planning 
and behaviour, or global mental health, but it did de-
crease symptoms of depression compared with women 
who were not invited for counselling. Trained doctors 
more often inquired about safety of women and children 
in the intervention group compared to those in the 
control group. We detected no diﬀ erences between the 
intervention and control groups in women’s anxiety 
symptoms or comfort to discuss fear.
By contrast with a primary care case-ﬁ nding trial,30 
our intervention did not focus only on referral (panel). 
Instead, doctors were trained to respond to women’s needs 
in view of the fact that many women are not ready to use 
counselling or IPV services at the point of identiﬁ cation.15 
Despite women having a range of IPV severities with poor 
mental health and quality of life at enrolment,29 use of IPV-
related services was low and much the same between 
groups at baseline and 6 month and 12 month follow-up, 
and not all women accepted the counselling invitation. 
Women in our trial who chose not to go to the intervention 
counselling sessions were not ready or perceived no need 
for them, were already seeing counsellors, or the trial 
doctor was not their usual doctor. In line with our ﬁ ndings, 
Intervention n (%) Comparison n (%)
6 months (n=94) 12 months (n=96) 6 months (n=99) 12 months (n=100)
I am glad to be a participant in the WEAVE project
Strongly agree 47 (51%) 54 (57%) 37 (38%) 47 (48%)
Agree 30 (33%) 30 (32%) 45 (46%) 37 (37%)
Neither agree nor disagree 12 (13%) 10 (11%) 16 (16%) 13 (13%)
Disagree 1 (1%) 1 (1%) 0 (0%) 1 (1%)
Strongly disagree 2 (2%) 0 (0%) 0 (0%) 1 (1%)
I felt judged negatively by practice staﬀ  (eg, nurses, receptionists) for being a participant in this trial
Strongly agree 0 (0%) 0 (0%) 1 (1%) 1 (1%)
Agree 2 (2%) 0 (0%) 1 (1%) 1 (1%)
Neither agree nor disagree 25 (28%) 23 (25%) 35 (36%) 26 (27%)
Disagree 20 (22%) 29 (31%) 20 (21%) 18 (19%)
Strongly disagree 44 (48%) 42 (45%) 40 (41%) 50 (52%)
As a result of participating in the trial, I see the quality of my own life as…
Better 21 (23%) 26 (27%) 15 (16%) 22 (23%)
Somewhat better 33 (36%) 31 (33%) 27 (28%) 25 (26%)
About the same as before 37 (40%) 34 (36%) 50 (53%) 47 (50%)
Somewhat worse 1 (1%) 4 (4%) 3 (3%) 1 (1%)
Worse 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Abusive partner’s awareness*
Aware she talked to the trial doctor about relationship issues at 6 months† 
or was involved in a project about relationship issues at 12 months
16/57 (28%) 23/95 (24%) 5/49 (10%) 12/96 (13%)
Consequences of abusive partner’s awareness‡
Positive partner behaviours per woman/number of women§ 0·5/16 0·7/23 0·8/5 0·3/12
Negative partner behaviours per woman/number of women¶ 1·6/16 0·3/23 3·0/5 0·2/12
Data are n (%) or n/N (%) unless otherwise stated. Some denominators vary because of missing data. *Items adapted from consequences of screening tool (appendix). 
†Denominator includes only women who had visited the trial doctor in the past 6 months. ‡Rate of positive and negative partner behavioural consequences per woman; only 
women who reported partner awareness of trial doctor discussion or trial involvement were asked to complete this item. §For example, improved his behaviour towards her, 
tried to do something about partner violence. ¶For example, got angry, made her more afraid for herself or her children, restricted her freedom.
Table 4: Women’s assessment of participating in the trial
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in an antenatal care trial of counselling from social workers 
for women receiving antenatal care,31 a quarter of women 
attended no sessions and half of women received less than 
the full quota oﬀ ered.
Strengths of our trial included the randomisation of 
doctors to minimise the risk of contamination, and the 
recruitment of doctors and women before allocation to 
study group to minimise selection bias. We accurately 
estimated loss of participants to follow-up in this trial 
(30%),8 which was similar to or lower than in other trials 
done in the past decade.3,23,31 Women lost to follow-up were 
not more likely to report IPV or depression at baseline, and 
those who actively withdrew gave similar reasons across 
study groups. No doctor withdrew from the trial and only 
24 women (9%) actively withdrew. We promoted safety 
using international guidelines1 and systematically assessed 
harm. Limitations of previous studies in this subject area 
have included lack of randomisation or baseline assess-
ment before randomisation, greater loss to follow-up than 
30%, lack of assessment of diﬀ erences between those lost 
to follow-up, and minimal assessment of harm.2
Our trial had several limitations. Recruitment of doc-
tors to this trial was low but similar to levels seen in other 
similar trials done in Australia, and resulted from using 
a strategy of extensive mail-out of invitations with little 
follow-up.32 Most doctors were women, and although the 
doctors might have been interested in the problem under 
investigation, very few had undertaken previous IPV 
training, and communication skills were similar to other 
populations of doctors.33 Most women who responded to 
screening invitations had more years of education than 
those that did not respond, were employed, and spoke 
English,26 which restricts the generalisabilty of our 
ﬁ ndings because our study population would not be 
applicable to, for example, refuge or shelter populations.7 
However, the prevalence of IPV in our screening sample 
(13%) was similar to that seen in larger surveys done in 
waiting rooms of primary-care clinics, in which a higher 
proportion of women responded to the survey (78%).34 
Masking of doctors and women during implementation 
was not feasible,3 and, because women’s outcomes were 
self-reported, there could have been some bias in 
response to survey questions. Another limitation is the 
potential for a so-called Hawthorne Eﬀ ect from the 
baseline surveys, which could have attenuated the inter-
vention eﬀ ect.3,35
Our ﬁ ndings do not lend support to the protocol 
hypothesis that increased support from doctors for 
women screening positive for IPV and discussion about 
safety with doctors would lead to improvement in 
women’s mental health, safety planning and behaviour, 
and quality of life. For women who are ready to accept 
help,15 trained doctors seemed to provide more support 
and inquired more often about their safety, and they were 
less likely to report depressive symptoms. We interpreted 
the 17% between-group diﬀ erence in reports of depressive 
symptoms as clinically relevant, and in line with ﬁ ndings 
from other studies testing interventions for depression.36 
No adverse events were reported and we detected no 
evidence of a diﬀ erence in harm or abuse between groups. 
The harm reported was at a similar level (4%) to the WHO 
multicountry study,1 with few women’s partners being 
aware that they were involved in the trial (table 4).
Future research could reﬁ ne and test interventions that 
improve the pathway from screening to counselling. We 
selected to post surveys to participants because evidence 
suggests that women prefer such distal methods of 
screening to face-to-face approaches.2 The WEAVE 
intervention’s reach could be broadened by, for example, 
doing screening in waiting rooms, using computerised 
methods of screening, oﬀ ering counselling to only 
women who would like help with the issue on that day, 
and follow-up of women not attending counselling, all of 
which have been shown to increase uptake of counselling 
or other interventions.3,11 Other recommendations for 
future primary care interventions include the provision of 
opportunities for multiple points of entry to coun selling 
that do not rely only on universal screening—for example, 
use of nurses and bicultural health workers to deliver the 
intervention, increase in the amount of training and 
inclusion of all primary care staﬀ , and the further tailoring 
of counselling to women’s diverse experiences. Removal 
of baseline surveys could eliminate the independent 
eﬀ ects of research participation (the Hawthorne eﬀ ect).
Panel: Research in context
Systematic review
 We updated previous systematic reviews2 and compared our results with a 
2004 systematic review.3 We searched Medline, Scopus, Cinahl, PsycINFO, and the 
Cochrane Library using the search terms “domestic violence”, “spouse abuse”, “battered 
women”, “screen*” “identif*” “interven*”, “counsel*” “advocacy” “health service” “primary 
care”, “general practice”, and “family doctor” for randomised clinical trials published in 
English from Jan 1, 2007, to March 1, 2012. We identiﬁ ed one primary care screening and 
intervention trial that showed no eﬀ ect of a nurse-led management protocol compared 
with the use of a wallet-sized referral card on reducing violence.6 In antenatal care, a 
safety-planning and empowerment intervention by nurses in Hong Kong and a 
psychosocial behavioural intervention for black women by social workers showed a 
reduction in minor physical violence.29,39 Screening trials by MacMillan and colleagues23 and 
Klevens and colleagues5 did not provide interventions post-screening and therefore cannot 
inform research into a response intervention for women identiﬁ ed through screening.23 
We were unable to ﬁ nd a primary care population intervention eﬀ ectiveness trial with 
quality of life and health outcomes for women identiﬁ ed through screening.
Interpretation
We know of no other randomised trial to test counselling delivered by family doctors for 
women identiﬁ ed through primary care-based screening for intimate partner violence. 
Our ﬁ ndings can help inform research into future steps for intervention research, but do 
not lend support to the use of a postal screening process. Training of doctors can 
successfully lead to more safety discussions with women, and greater identiﬁ cation and 
referral to services.30 However, greater attention needs to be paid to the pathway from 
identiﬁ cation of women through to attendance at supportive counselling. Future 
interventions need reﬁ nement to be tailored to the diverse needs of women at diﬀ erent 
points in the trajectory of abuse and help-seeking. 
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Recent recommendations from the US Preventive Task 
Force4 for post-screening intervention are mainly based 
on the ﬁ ndings of one good quality antenatal care trial.31 
Rates of screening female patients for IPV in health-care 
settings are often low, with many barriers to increasing 
screening.2 Findings from a review of international 
studies reported a median screening rate of 19% of 
patients, based on the 11 studies that examined data on 
the basis of patients’ self-reports.37 Our ﬁ ndings add to 
this evidence base in primary care by suggesting that 
postal screening might not reach a large proportion of 
women. Furthermore, although doctors can be trained to 
discuss safety of women and children and to invite 
women for brief counselling with consequent reductions 
in depressive symptoms, there is no eﬀ ect on women’s 
quality of life, safety planning and behaviour, and global 
mental health at 12 months. In keeping with other trials 
that assessed only screening,5,23 this trial does not lend 
support to screening for IPV in health-care settings. 
More research is urgently needed into how to increase 
identiﬁ cation of women who experience IPV and into 
what interventions would help women achieve safer, 
healthier lives.38
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